stockrow
Friday 6 November 2026
Export RPRX’s income statement to Excel — free account
Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
67.59
0.02
+0.03%
Follow RPRX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 6 | 4 | 4 | — | — | — | — |
P/E ratio |
21.71 | 13.22 | 13.03 | 492.50 | 39.07 | 41.36 | 66.51 | 66.51 | — |
Altman Z-Score |
1.61 | 1.48 | 1.94 | 1.88 | 2.13 | 2.65 | — | — | — |
P/S ratio |
6.98 | 5.05 | 5.37 | 7.71 | 7.22 | 8.85 | 0.00 | 0.00 | — |
P/FCF ratio |
4.72 | 4.16 | 3.78 | 8.13 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
2.25 | 2.56 | 3.24 | 2.42 | 3.46 | 3.73 | 3.44 | — | — |
Beneish M-Score |
(2.83) | (2.62) | (2.97) | (3.50) | (2.13) | (2.55) | — | — | — |
P/Operating CF |
20.08 | 15.40 | 16.38 | 30.28 | 33.74 | 33.22 | 0.00 | 0.00 | — |
P/B ratio |
1.71 | 1.11 | 1.25 | 1.81 | 1.61 | 1.90 | 0.00 | 0.00 | — |
Dividend Safety Score |
41 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
1.89 | 1.11 | 1.26 | 1.81 | 1.61 | 1.90 | 0.00 | 0.00 | — |
EV/Sales |
10.48 | 7.98 | 8.19 | 10.12 | 9.44 | 10.71 | 0.00 | 0.00 | — |
EV/EBITDA |
15.65 | 13.76 | 12.75 | 67.75 | 14.67 | 13.94 | 0.00 | 0.00 | — |
EV/Operating CF |
10.01 | 6.52 | 6.46 | 10.56 | 10.72 | 11.17 | 2.77 | 2.77 | — |
EV/FCF |
7.09 | 6.56 | 5.77 | 10.66 | (124.27) | (153.96) | 18.65 | 18.65 | — |
Quick Ratio |
1.05 | 0.81 | 3.21 | 1.52 | 13.18 | 6.82 | 1.14 | — | — |
Current Ratio |
2.40 | 1.44 | 7.90 | 2.19 | 16.81 | 8.76 | 2.50 | — | — |
Net Debt/EBITDA |
5.22 | 5.05 | 3.73 | 16.10 | 3.33 | 2.30 | 2.23 | 0.00 | — |
Debt/Assets |
45.62% | 41.77% | 37.45% | 42.33% | 40.51% | 36.31% | 50.33% | 0.00% | 0.00% |
Debt/Equity |
0.92 | 0.74 | 0.61 | 0.75 | 0.69 | 0.59 | 1.02 | 0.00 | — |
Asset Turnover |
0.13 | 0.13 | 0.14 | 0.13 | 0.14 | 0.15 | 0.29 | 0.00 | — |
Operating CF/Net income |
3.23 | 3.22 | 2.63 | 50.06 | 3.26 | 2.09 | 0.71 | 1.17 | — |
Capex/Depreciation |
0.00 | (0.92) | 0.00 | (0.78) | (50.78) | (62.76) | (46.88) | (5.81) | — |
Interest Coverage |
5.07 | 5.73 | 7.97 | 1.63 | 8.61 | 10.16 | 9.77 | 4.87 | — |
| 7.69% | 8.41% | 11.57% | 0.43% | 6.15% | 12.16% | 29.29% | 0.00% | — | |
| 4.07% | 4.96% | 6.84% | 0.25% | 3.70% | 6.85% | 37.73% | 0.00% | — | |
ROIC |
5.41% | 4.76% | 5.93% | 1.29% | 5.90% | 7.30% | 13.59% | 0.00% | — |
Return on Tangible Assets |
4.51% | 5.48% | 7.47% | 0.29% | 3.77% | 6.61% | 20.71% | 0.00% | — |
Average Days of Receivables |
4.50 | 4.35 | 3.47 | 5.97 | 10.89 | 6.74 | 7.80 | 0.00 | — |
Research and Development Expense of Revenue |
19.01% | 0.09% | 2.21% | 7.92% | 8.74% | 1.24% | 4.58% | 21.87% | — |
Selling, General and Administrative Expense of Revenue |
24.11% | 10.46% | 10.61% | 10.16% | 7.99% | 8.56% | 5.70% | 3.45% | — |
Intangible Assets out of Total Assets |
0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.19% | 0.10% | 0.10% | 0.10% | 0.11% | 0.26% | 0.00% | 0.00% | — |
Graham Net Nets |
(0.50) | (0.53) | (0.40) | (0.27) | (0.27) | (0.18) | 0.00 | 0.00 | — |
Graham Number |
30.09 | 31.66 | 33.17 | 6.26 | 23.81 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
4.61% | 7.57% | 7.68% | 0.20% | 2.56% | 2.42% | 1.50% | 1.50% | — |
Free Cash Flow Yield |
21.18% | 24.06% | 26.43% | 12.30% | (1.05%) | (0.79%) | 0.00% | 0.00% | — |
Revenue per Share |
5.53 | 5.05 | 5.26 | 5.11 | 5.52 | 5.65 | 4.83 | 0.00 | — |
Operating CF per Share |
5.79 | 6.18 | 6.68 | 4.90 | 4.86 | 5.42 | 4.44 | 0.00 | — |
Capex per Share |
0.00 | (0.04) | 0.00 | (0.05) | (5.28) | (5.81) | (4.58) | 0.00 | — |
Free Cash Flow per Share |
5.79 | 6.14 | 6.68 | 4.85 | (0.42) | (0.39) | (0.14) | 0.00 | — |
Cash per Share |
1.48 | 2.20 | 1.11 | 3.96 | 5.28 | 5.49 | 0.91 | — | — |
Shareholders Equity per Share |
22.60 | 23.08 | 22.53 | 21.75 | 24.71 | 26.36 | 16.36 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
22.60 | 23.08 | 22.53 | 21.75 | 24.71 | 26.36 | 16.36 | 0.00 | — |
Free Cash Flow |
2,489.82 | 2,750.99 | 2,987.80 | 2,122.77 | (173.97) | (147.62) | (54.05) | 1,348.72 | — |
Working Capital |
891.88 | 548.52 | 1,112.82 | 1,388.13 | 2,706.96 | 2,389.01 | 498.66 | — | — |
Capital Expenditures |
— | (18.00) | — | (21.21) | (2,191.50) | (2,182.25) | (1,721.29) | (269.59) | — |
Net Current Asset Value |
(8,377.75) | (6,078.21) | (5,023.37) | (4,733.18) | (4,389.11) | (3,427.57) | (5,476.38) | 0.00 | — |
EV/EBIT |
15.98 | 13.97 | 12.93 | 73.72 | 15.11 | 14.25 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | 0.96 | 1.03 | 0.95 | 0.15 | — |
Price to Operating Income |
10.65 | 8.85 | 8.48 | 56.20 | 11.55 | 11.78 | 10.54 | 10.54 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Cash ROIC |
12.90% | 14.52% | 17.88% | 11.55% | (0.89%) | (0.83%) | (0.42%) | 0.00% | — |
Accounts Receivable Turnover |
84.52 | 91.72 | 79.81 | 42.65 | 42.60 | 54.47 | 46.56 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
28.14 | 24.68 | 29.50 | 52.45 | 53.74 | 38.97 | 38.97 | — | — |
Average Payables |
16.39 | 14.27 | 11.54 | 6.76 | 8.20 | 10.98 | 10.98 | — | — |
Average Assets |
18,921.75 | 17,302.28 | 16,597.66 | 17,164.67 | 16,768.08 | 14,235.09 | 6,224.95 | 0.00 | — |
Average Common Equity |
10,028.65 | 10,213.33 | 9,804.83 | 9,886.96 | 10,072.18 | 8,018.63 | 8,018.63 | — | — |
Columns are period end dates · fundamentals updated 5 Nov 2026